Why the study?
Does baseline JCV positive status worsen clinical and radiological disease activity in RRMS patients treated with Natalizumab?
Does baseline JCV positive status worsen clinical and radiological disease activity in RRMS patients treated with Natalizumab?
Baseline JCV seropositivity does not appear to influence the short-term clinical or radiological disease course in patients with relapsing-remitting multiple sclerosis treated with Natalizumab.
JCV status showed no short-term impact on natalizumab outcomes in RRMS; leaves open longer-term disability effects and risk stratification.
We prospectively assessed the influence of JCV- status on disability’s accrual in RRMS patients treated with Natalizumab at two tertiary MS centres, settled in Italy. Negative binomial model was used to assess the influence of baseline JCV status (positive or negative) treatment on clinical and radiological disease activity during the 24 months’ follow-up. One hundred eighty four patients treated with Natalizumab were enrolled (83 JCV +, whilst 101 JCV-). Over the two years of follow-up there was not significant clinical and radiological differences between the two groups. JCV + RRMS did not showed a severe clinical course than JCV – RRMS.
No takes yet. Share an insight, caveat, or question.
D’Amico et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: